Applications of DNA vaccines in veterinary medicine

Document Type : Scientific-Extensional Article

Authors

1 Student of Veterinary Medicine, Shahrekord University, Shahrekord, Iran

2 Assistant Professor, Department of Animal Science, Faculty of Agriculture, Shahrekord University, Shahrekord, Iran

Abstract

DNA vaccine consists of a plasmid DNA molecule that contains gene(s) expressing the desired antigen and suitable genetic elements (such as promoter) for expression in the target organism. The antigen is recognized by the immune system of the target organism and a humoral or cellular immune response is created. DNA vaccines have many advantages over conventional vaccines, including ease of production, stability, and the ability to produce on a large scale. They overcome the need to culture dangerous infectious agents and allow vaccination against multiple pathogens in a single injection. Because DNA vaccine plasmids are non-living, non-replicating and non-propagating, there is little risk of reversion to the disease-causing form or secondary infection. In addition to safety, DNA vaccines are very flexible and can be made by several types of genes, including viral or bacterial antigens, and produce immunological and biological proteins. In the recent years, four DNA products have been licensed for animal use, which are vaccines against West Nile virus in horses, infectious necrosis virus of hematopoietic centers in cultured salmon, melanoma in dogs, and a growth hormone-releasing hormone product (GHRH) for fetal loss in pigs. Production on a large scale and at low cost have made the production of DNA vaccines successful in the commercial arena. Nevertheless, more researches are needed to solve the limitations of using this type of vaccines in livestock.

Keywords

References

Bergman, P. J., Camps-Palau, M. A., McKnight, J. A., Leibman, N. F., Craft, D. M., and et al. (2006). "Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center." Vaccine, 24(21):4582-5.
Dhama, K., Chauhan, R. S., Mahendran, M., Singhal, L. (2007). "DNA vaccines and prevention of infectious diseases in bovines: A Review." International Journal of Cow Science. 3(2):1-2.
Dhama, K., Mahendran, M., Gupta, P. K., Rai, A. (2008). "DNA vaccines and their applications in veterinary practice: current perspectives." Veterinary Research Communications. 32:341-56.
Dufour, V. (2001). "DNA vaccines: new applications for veterinary medicine." Veterinary Sciences Tomorrow. 2:1-26.
Dunham, S. P. (2002). "The application of nucleic acid vaccines in veterinary medicine." Research in Veterinary Science. 1; 73(1):9-16.
Haygreen, L., Davison, F., Kaiser, P. (2005). "DNA vaccines for poultry: the jump from theory to practice." Expert Review of Vaccines. 1; 4(1):51-62.
Khusro, A., Aarti, C., Rivas-Caceres, R. R., Barbabosa-Pliego, A. (2020). "Equine herpesvirus-I infection in horses: Recent updates on its pathogenicity, vaccination, and preventive management strategies." Journal of Equine Veterinary Science. 1; 87:102923.
Liu, M. A. (2003). "DNA vaccines: a review." Journal of Internal Medicine. 253(4):402-10.
Lopes, A., Vandermeulen, G., Préat, V. (2019). "Cancer DNA vaccines: current preclinical and clinical developments and future perspectives." Journal of Experimental & Clinical Cancer Research. 38:1-24.
Lowe, D. B., Shearer, M. H., Kennedy, R. C. (2006). "DNA vaccines: successes and limitations in cancer and infectious disease." Journal of Cellular Biochemistry. 15; 98(2):235-42.
Olsen, C. W. (2000). "DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza." Veterinary Microbiology. 22; 74(1-2):149-64.
Pasandideh, R., Seyfi Abad Shapouri, M. R., Beigi Nassiri, M. T. (2018). "Immunogenicity of a plasmid DNA vaccine encoding G1 epitope of bovine ephemeral fever virus G glycoprotein in mice." Onderstepoort Journal of Veterinary Research. 85 (1): 1617.
Pereira, V. B., Zurita-Turk, M., Saraiva, T. D., Castro, C. P., Souza, B. M., et al. (2014). "DNA vaccines approach: from concepts to applications." World Journal of Vaccines, 4, 50-71.
Reyes-Sandoval, A., Ertl, H. C. (2001). "DNA vaccines." Current Molecular Medicine. 1(2):217-43.
Saade, F., Petrovsky, N. (2012). "Technologies for enhanced efficacy of DNA vaccines." Expert Review of Vaccines. 1; 11(2):189-209.
Saiz, J. C. (2020). "Animal and human vaccines against West Nile virus." Pathogens. 21; 9(12):1073.
Schumacher, D., Tischer, B. K., Fuchs, W., Osterrieder, N. (2000). "Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant." Journal of Virology. 74(23), 11088–11098.
Sommerville, L. M., Radford, A. D., Glenn, M., Dawson, S., Gaskell, C. J., et al. (2002). "DNA vaccination against feline calicivirus infection using a plasmid encoding the mature capsid protein." Vaccine. 15; 20(13-14):1787-96.
Starodubova, E. S., Preobrazhenskaia, O. V., Kuzmenko, Y. V., Latanova, A. A., Yarygina, E. I., Karpov, V. L. (2015). "Rabies vaccines: Current status and prospects for development." Molecular Biology.49:513-9.
Van Drunen Littel‐van den Hurk, S., Babiuk, S. L., Babiuk, L. A. (2004). "Strategies for improved formulation and delivery of DNA vaccines to veterinary target species." Immunological Reviews. 199(1):113-25.
Professional Journal of Domestic
Volume 23, Issue 3 - Serial Number 27
In progress
March 2024
Pages 32-38

Files

Share

How to cite

Statistics